The Phase 2b ORIGIN clinical trial is a dose-ranging study evaluating the safety and efficacy of atacicept in patients with IgA nephropathy (IgAN) who continue to have persistent proteinuria and remain at high risk of disease progression. Find out more here.
The Phase 2b ORIGIN study is a clinical trial to validate atacicept’s efficacy and safety in IgAN. Find out more here.
Clinicaltrials.gov is a regulatory public registry of clinical trials. To learn more about Vera or other clinical trials, their designs, purpose, eligibility criteria, and study locations, you can search at Clinicaltrials.gov.
Reactivation of BK Virus (BKV) can have serious consequences for immunocompromised patients, including kidney transplant and hematopoietic stem cell transplant (HSCT) recipients.
We are currently conducting a Ph2 study to evaluate efficacy and safety of MAU868 in the treatment of BK viremia in kidney transplant recipients. Find out more here.